A3P Biomedical stock
Last updated
A3P Biomedical är ett svenskt företag inom medicinsk diagnostik fokuserat på prostatacancer. De tar fram avancerade testmetoder för att erbjuda tidigare och mer precisa diagnoser vilket kan leda till bättre behandlingsresultat och minskade sjukvårdskostnader.
Note: Information on A3P Biomedical is sourced from official channels and public sources unless otherwise stated.
A3P Biomedical new issues and valuations
| Date | Type | Share price | Amount The specific amount raised in this funding round. | Valuation The company's valuation after the funding round was completed (Post-money). |
|---|---|---|---|---|
| Q2 2022 | 23.83 SEK | SEK 13,600,000 | SEK 1,213,500,000 | |
| Q2 2022 | 23.83 SEK | SEK 400,000,000 | SEK 1,200,000,000 | |
| Q3 2021 | 20 SEK | SEK 3,300,000 | SEK 671,300,000 |
Note: Information on A3P Biomedical's funding rounds, amounts, and valuation is sourced from news media and public sources unless otherwise stated. Information on capital structure is sourced from public company registers unless otherwise stated.
About the company
Business description is not available at this time.
Major Shareholders in A3P Biomedical
| Name | Shares | Capital % |
|---|---|---|
| TomEnterprise Private AB | 14,929,640 | 29.3% |
| MARTIN STEINBERG | 5,195,500 | 10.2% |
| OLA STEINBERG | 5,195,500 | 10.2% |
| HENRIK GRÖNBERG | 4,526,600 | 8.9% |
Note: Information on A3P Biomedical's ownership structure is sourced from public company registers and external data providers unless otherwise stated. Source: Eivora (9/5/2025).
A3P Biomedical stock: key facts
Note: Information sourced from official company registrations and public sources unless otherwise stated.
Active market
Settlement follows an established process with third-party verification of payment and share transfer, minimizing counterparty risk for both parties.
Securities shown in the view above are for illustrative purposes only.
News about A3P Biomedical
Nyvalde styrelseordförande Christopher O’Connell och VD Martin Steinberg leder A3Ps nästa tillväxtfas
Årsstämman i A3P Biomedical AB (publ) (“A3P”) har utsett Christopher O’Connell till ny styrelseordförande. Samtidigt utsågs Martin Steinberg, medgrundare av bolaget och tidigare styrelseordförande, till verkställande direktör och kommer även fortsättningsvis att ingå i styrelsen. Christopher O’Connell, med mer än tre decenniers global ledarerfarenhet inom life science, har varit ledamot i A3Ps styrelse sedan 2025 och kommer att leda styrelsens arbete med att stödja bolagets fortsatta utveckling och strategigenomförande.
A3P Biomedical appoints Christopher O’Connell as Board Director
A3P Biomedical AB (publ) (A3P) is pleased to announce the appointment of Christopher O’Connell, who brings exceptional strategic and operational experience to the company, as Board Director.
Flerie säljer hela innehavet i A3P Biomedical
Flerie Invest har avyttrat samtliga sina aktier i A3P Biomedical, ett portföljbolag inom prostatacancerdiagnostik, för totalt 71,3 miljoner kronor. Ägarandelen uppgick till 8 procent av A3P och försäljningen sker till en värdering 55 procent över det senast rapporterade verkliga värdet för Fleries innehav.
Buy A3P Biomedical shares
Place a bid on A3P Biomedical shares. View historical prices and access unique company data.
Buy shares in A3P BiomedicalHelp for new buyers
Sell A3P Biomedical shares
Unlock capital from your unlisted holding. Accumeo matches you with buyers and handles settlement through an established process.
Sell shares in A3P BiomedicalHelp for new sellers
Have any questions about buying or selling shares in private companies? Don't hesitate to contact us.
FAQ
A3P Biomedical is an unlisted company, meaning the shares are not traded on any exchange. Instead, transactions take place through direct transfers between parties, known as secondary trading, typically via a specialised platform for unlisted shares such as Accumeo. For larger international companies, investing through fund structures that pool several investors into a single ownership vehicle is also common. This allows smaller minimum investments and opens up access to international companies for non-institutional investors.
Yes, it is possible to buy existing shares in A3P Biomedical through secondary trading. On Accumeo you create a free account, submit an expression of interest with an amount and any conditions, and may then be matched with a seller. Once both parties have signed the customer agreement, a share transfer agreement is drawn up covering price, share count, and settlement date.
Yes, secondary trading is often the only realistic route to liquidity for an unlisted holding before an IPO or acquisition. Via Accumeo you submit an expression of interest with a share count and target price, and a match may be made with a potential buyer. The sale is executed through a share transfer agreement and registered either via Euroclear or directly in the company's share register, depending on how ownership is administered.
Unlisted companies have no continuous share price because there is no continuous exchange trading. The value is instead based on the latest secondary-market trade or on the price per share from the most recent share issuance. Accumeo shows both historical transaction prices and current bid/ask quotes, providing a combined reference point for pricing.
The value of an unlisted share is most often based on the latest trade — the price buyer and seller agreed in a transaction — or on the latest funding round, where the company and its investors agreed a price for the newly issued shares. These are the reference points shown on Accumeo's platform. It is, however, important to form your own view of value by examining the company's prospects. Financial reports, growth opportunities, market position, and comparable transactions in the sector all help to build a better picture of how the business may develop. Useful information can be found on the company's own website, via Accumeo's platform, and on services like allabolag.se.
No, A3P Biomedical is an unlisted company and its shares are not traded on the Stockholm Stock Exchange, NYSE, or any other regulated marketplace. Shares are instead traded through secondary trading between investors, typically via a specialised platform such as Accumeo.
Disclaimer: The information in this FAQ is provided for informational purposes only and does not constitute an offer to buy or sell securities, a solicitation of such an offer, or investment advice. Accumeo has no commercial relationship with the companies whose securities are mentioned. Independent advice should be obtained before making any investment decision.
Other companies you may be interested in
BioCrine
BioCrine is a Swedish biotech company developing diabetes therapies based on advanced research in insulin secretion, insulin resistance, and pancreatic beta cell function, aiming to improve treatment outcomes and create sustainable long term value.
Sigrid Therapeutics
Sigrid Therapeutics is a Swedish clinical biotechnology company developing innovative solutions to prevent and treat lifestyle-related diseases. The company was founded in 2014 by Prof. Tore Bengtsson and Sana Alajmovic with the vision to change the way we manage modern chronic diseases. Their technology, SiPore®, consists of precision-engineered mesoporous silica particles that act in the gut to improve blood sugar control in a safe and effective way. The lead product, SiPore21®, is an oral medical device in clinical development, intended to improve metabolic function in people with prediabetes and new-onset type 2 diabetes. Sigrid Therapeutics is headquartered in Stockholm and is part of Karolinska Innovation's incubator program for promising life science startups in Sweden.
Gradientech
Gradientech is a Swedish in vitro diagnostics company specializing in ultra-fast antibiotic susceptibility testing (AST). Their flagship product, QuickMIC®, is designed to empower modern microbiology laboratories by delivering accurate minimum inhibitory concentration (MIC) values directly from positive blood cultures within 2-4 hours. The technology enables faster and more informed treatment decisions, improving healthcare and reducing the spread of antibiotic resistance.
Werlabs
Werlabs provides digital health checkups based on blood tests, blood pressure and lifestyle data, partnering with accredited Swedish laboratories and delivering doctor-reviewed results through a secure online health journal.
Kry
Kry är ett digitalt vårdbolag som erbjuder tillgång till sjukvård genom videomöten, chattar och fysiska kliniker. Bolaget kombinerar medicinsk expertis med egenutvecklad teknik för att göra vården mer tillgänglig, effektiv och patientfokuserad. Genom sin plattform kan patienter snabbt få kontakt med läkare, psykologer och sjuksköterskor, både digitalt och på plats, vilket bidrar till en mer sammanhållen och modern vårdupplevelse.
Mindler
Mindler is a Swedish digital healthcare company that offers psychological treatment via an app. The company was founded in 2018 with the goal of making psychological help more accessible and effective through digital solutions. Mindler combines video-based conversations with licensed psychologists and digital self-help programs. By offering fast and flexible access to psychological care, Mindler helps to reduce waiting times and improve the mental health of individuals.*The information is based on estimates of the latest new issue and may be updated.
Doktor.se
Doktor.se is one of Sweden's largest healthcare providers, founded in 2016, offering both digital and physical healthcare. The company operates healthcare centres across the country and has approximately 1,250 employees.through its app, patients can quickly get in touch with licensed healthcare professionals for advice, prescription renewal and assessment of various health conditions. Doktor.se aims to streamline and increase accessibility in Swedish healthcare by combining digital services with traditional care.
Neko Health
Neko Health is a Swedish health and medical technology company specializing in advanced whole-body scanning for early detection of health problems. Their innovative scanning systems use advanced sensors and AI-powered analytics to identify abnormalities in the skin, cardiovascular system and other vital parameters in minutes. By offering a fast, accurate and comprehensive health check, Neko Health enables individuals to proactively monitor their health and for healthcare providers to make more informed decisions, which can contribute to earlier diagnoses and improved disease prevention.
FirstVet
FirstVet is a Swedish digital veterinary clinic founded in 2016 by David Prien, Per Victor, Joakim Widigs and Lars-Martin Norviit. The service offers pet owners the opportunity to consult with licensed veterinarians via an app or website through video calls, providing quick access to advice, treatment or referral without having to visit a physical clinic.
Start exploring unlisted shares today
Join 5,000+ investors already trading unlisted shares. Create an account in 2 minutes with BankID — completely free.